NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

NCCR AntiResist

NCCR AntiResist

New approaches to combat antibiotic-resistant bacteria

Revitalizing antibiotic discovery by a patient-centered paradigm shift

Antibiotics are powerful and indispensable drugs to treat life threatening bacterial infections, such as sepsis or pneumonia. Antibiotics also play a central role in many other areas of modern medicine, in particular to protect patients with a weakened immune system during cancer therapies, transplantations or surgical interventions. These achievements are now at risk, with the fraction of bacterial pathogens that are resistant to one or more antibiotics steadily increasing.

The discovery and development of novel antibiotics faces complex societal, economic, technological and scientific challenges. The declining pipeline for novel antibiotics and increasing resistance to existing drugs gradually reduces the options clinicians have to treat bacterial infections.

NCCR AntiResist

The National Center of Competence in Research AntiResist aims to bring about a paradigm shift in antibiotic research with an interdisciplinary approach that assembles a Swiss-wide network of research groups from the fields of clinical research, biology, chemistry, computation, engineering and pharmacology.

The research program is structured into three four-year phases covering strategically and dynamically evolving milestones. Research activities center around a better understanding of pathogen physiology in patients; developing axenic and tissue-based model systems mimicking patient environments; and engineering of novel screening platforms for the next generation of antibiotics.

NCCR AntiResist is funded by the Swiss National Science Foundation, and the home institution is the University of Basel.

Watch our 3-Minute YouTube video produced by the University of Basel.